Effect of metabolic inhibitors on cyclosporine pharmacokinetics using a population approach

Therapeutic Drug Monitoring

Volumn 20, Issue 4, 1998, Pages 390-395

  McLachlan, Andrew J ^a   Tett, Susan E ^a,b  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Cyclosporine; Diltiazem; Drug interactions; Ketoconazole; Population pharmacokinetics

Indexed keywords

AZATHIOPRINE; CAPTOPRIL; COTRIMOXAZOLE; CYCLOSPORIN; DILTIAZEM; FUROSEMIDE; HYDRALAZINE; ITRACONAZOLE; KETOCONAZOLE; NIFEDIPINE; PREDNISONE; RANITIDINE; SIMVASTATIN;

ARTICLE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG METABOLISM; HEART TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; METABOLIC INHIBITION; POPULATION RESEARCH; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; CALCIUM CHANNEL BLOCKERS; CHILD; CYCLOSPORINE; DILTIAZEM; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FLUCONAZOLE; HEART-LUNG TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INDIVIDUALITY; ITRACONAZOLE; KETOCONAZOLE; LINEAR MODELS; MIDDLE AGED;

EID: 0031875225     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199808000-00007     Document Type: Article

References (24)

1. Campana C, Regazzi MB, Buggia I, Molinaro M. Clinically significant drug interactions with cyclosporin: an update. Clin Pharmacokinet 1996;30:141-79.
2. Keogh A, Spratt P, McCosker C, MacDonald P, Mundy J, Kaan A. Ketoconazole to reduce the need for cyclosporine after cardiac transplantation. N Engl J Med 1995;333:628-33.
3. Jones TE. The use of other drugs to allow a lower dosage of cyclosporine to be used. Clin Pharmacokinet 1997;32:357-67.
4. Jones TE. Survey of cyclosporine-sparing agent use in Australasian transplant centres. Aust NZ J Med 1996;26:772-6.
5. Grevel J, Post BK, Kahan BD. Michaelis-Menten kinetics determine cyclosporine steady-state concentrations: a population analysis in kidney transplant patients. Clin Pharmacol Ther 1993;53: 651-660.
6. Mentre F, Mallet A, Steimer JL, Lokiec F. An application of population pharmacokinetics to the clinical use of cyclosporine in bone marrow transplant patients. Transplant Proc 1988;20(suppl 1): 466-70.
7. Mallet A , Mentre F, Steimer JL, Lokiec F. Nonparametric maximum likelihood estimation for population pharmacokinetics, with application to cyclosporine. J Pharmacokinet Biopharm 1988;16: 311-27.
8. Whiting B, Niven A, Kelman AW, et al. A Bayesian kinetic control strategy for cyclosporine in renal transplantation. Advanced Methods of Pharmacokinetic and Pharmacodynamic Systems Analysis. In: DíArgenio DZ. New York: Plenum Press; 1991.
9. Anderson JE, Munday AS, Kelman AW, et al. Evaluation of a Bayesian approach to the pharmacokinetic interpretation of cyclosporine concentrations in renal allograft recipients. Ther Drug Monit 1994;16:160-5.
10. Akhlaghi F, McLachlan AJ, Keogh AM, Brown KF. Effect of simvastatin on cyclosporine unbound fraction and apparent blood clearance in heart transplant recipients. BrJ Clin Pharmacol 1997; 44:537-42.
11. Yatscoff RW, Copeland KR, Faraci CJ. Abbott TDx monoclonal antibody assay evaluated for measuring cyclosporine in whole blood. Clin Chem 1990;36:1969-73.
12. Gomeni R, Pineau G, Mentre F. Population kinetics and conditional assessment of the optimal dosage regimen using the P-PHARM software package. Anticancer Res 1994;14:2321-6.
13. Kinowski JM, Bressolle F, Rodier M, et al. A limited sampling model with Bayesian estimation to determine inulin pharmacokinetics using the population data modelling program P-PHARM. Clin Drug Invest 1995;9:260-9.
14. Whiting B, Kelman AW, Grevel J. Population pharmacokinetics: theory and clinical application. Clin Pharmacokinet 1985;11:387-401.
15. Grevel J Area-under-the-curve versus trough level monitoring of cyclosporine concentration: critical assessment of dosage adjustment practices and measurements of clinical outcome. Ther Drug Monit 1993;15:488-91.
16. Cantarovich F, Cantarovich D, Touraine JL, et al. Cyclosporine dose adjustment in patients with normal serum creatinine and trough levels: a challenge for successful long term treatment. Transplant Proc 1989;21:1446-8.
17. Morris RG, Tett SE, Ray JE. Cyclosporine A monitoring in Australia: consensus recommendations. Ther Drug Monit 1994;16: 570-6.
18. Ohlman S, Lindholm A, Hagglund H, Sawe J, Kahan BD. On the intraindividual variability and chronobiology of cyclosporine pharmacokinetics in renal transplantation. Eur J Clin Pharmacol 1993; 44:265-9.
19. Gomez DY, Wacher VJ, Tomlanovich SJ, Hebert MF, Benet LZ. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther 1995;58:15-9.
20. Kramer MR, Marshall SE, Denning DW, et al. Cyclosporine and itraconazole interaction in heart and lung transplant recipients. Ann Int Med 1990;1134:327-9.
21. Back DJ, Tjia JF. Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporine by human liver microsomes. Br J Clin Pharmacol 1991;32:624-6.
22. Jones TE, Morris RG, Mathew TH. Diltiazem-cyclosporine pharmacokinetic interaction: dose-response relationship. Br J Clin Pharmacol 1997;44:499-504.
23. Ludden TM. Evaluation of potential drug-drug interactions using the population approach. In: Balant LP, Aarons L, eds. The Population Approach: Measuring and Managing Variability in Response, Concentration and Dose. Brussels: Commission of the European Communities, European Cooperation in the Field of Scientific and Technical Research; 1997:39-46.
24. Fuhr U, Weiss M, Kroemer HK, et al. Systematic screening of pharmacokinetic interactions during drug development. Int J Clin Pharmacol Ther 1996;34:139-51.